[1] |
PEKER B O, ENER A G, KAPTAN AYDOMU F. Antinuclear antibodies(ANAs)detected by indirect immunofluorescence(IIF)method in acute COVID-19 infection;future roadmap for laboratory diagnosis[J]. J Immunol Methods, 2021, 499:113174.
DOI
URL
|
[2] |
SAAD M A, ALFISHAWY M, NASSAR M, et al. COVID-19 and autoimmune diseases:a systematic review of reported cases[J]. Curr Rheumatol Rev, 2021, 17(2):193-204.
|
[3] |
MERONI P L, SCHUR P H. ANA screening:an old test with new recommendations[J]. Ann Rheum Dis, 2010, 69(8):1420-1422.
DOI
URL
|
[4] |
刘洁, 赵剑虹, 高艳, 等. 加温灭活对SARS-CoV-2咽拭子样本核酸检测结果的影响[J]. 检验医学, 2020, 35(5):405-408.
|
[5] |
中华人民共和国国家卫生健康委员会办公厅, 中华人民共和国国家中医药管理局办公室. 新型冠状病毒肺炎诊疗方案(试行第九版)[J]. 中国医药, 2022, 17(4):481-487.
|
[6] |
DAMOISEAUX J, ANDRADE L E C, CARBALLO O G, et al. Clinical relevance of HEp-2 indirect immunofluorescent patterns:the International Consensus on ANA patterns(ICAP) perspective[J]. Ann Rheum Dis, 2019, 78(7):879-889.
DOI
URL
|
[7] |
CHAN E K L, VON MÜLLEN C A, FRITZLER M J, et al. The International Consensus on ANA Patterns(ICAP) in 2021-the 6th workshop and current perspectives[J]. J Appl Lab Med, 2022, 7(1):322-330.
DOI
URL
|
[8] |
VOJDANI A, KHARRAZIAN D. Potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases[J]. Clin Immunol, 2020, 217:108480.
DOI
URL
|
[9] |
SALLE V. Coronavirus-induced autoimmunity[J]. Clin Immunol, 2021, 226:108694.
DOI
URL
|
[10] |
KANDUC D, SHOENFELD Y. Molecular mimicry between SARS-CoV-2 spike glycoprotein and mammalian proteomes:implications for the vaccine[J]. Immunol Res, 2020, 68(5):310-313.
DOI
|
[11] |
ZUO Y, ESTES S K, ALI R A, et al. Prothrombotic antiphospholipid antibodies in COVID-19[J]. medRxiv, 2020, 2020:20131607.
|
[12] |
TAN C W, LOW J G H, WONG W H, et al. Critically ill COVID-19 infected patients exhibit increased clot waveform analysis parameters consistent with hypercoagulability[J]. Am J Hematol, 2020, 95(7):E156-E158.
|
[13] |
BASTARD P, ROSEN LB, ZHANG Q, et al. Autoantibodies against type Ⅰ IFNs in patients with life-threatening COVID-19[J]. Science, 2020, 370(6515):eabd4585.
|
[14] |
MULLER S, RADIC M. Oxidation and mitochondrial origin of NET DNA in the pathogenesis of lupus[J]. Nat Med, 2016, 22(2):126-127.
DOI
PMID
|
[15] |
APEL F, ZYCHLINSKY A, KENNY E F. The role of neutrophil extracellular traps in rheumatic diseases[J]. Nat Rev Rheumatol, 2018, 14(8):467-475.
DOI
PMID
|
[16] |
WIGERBLAD G, KAPLAN M J. NETs spread ever wider in rheumatic diseases[J]. Nat Rev Rheumatol, 2020, 16(2):73-74.
DOI
PMID
|
[17] |
ALI R A, GANDHI A A, MENG H, et al. Adenosine receptor agonism protects against NETosis and thrombosis in antiphospholipid syndrome[J]. Nat Commun, 2019, 10(1):1916.
DOI
PMID
|
[18] |
NARASARAJU T, TANG B M, HERRMANN M, et al. Neutrophilia and NETopathy as key pathologic drivers of progressive lung impairment in patients with COVID-19[J]. Front Pharmacol, 2020, 11:870.
DOI
PMID
|
[19] |
TOMAR B, ANDERS H J, DESAI J, et al. Neutrophils and neutrophil extracellular traps drive necroinflammation in COVID-19[J]. Cells, 2020, 9(6):1383.
DOI
URL
|
[20] |
BARNES B J, ADROVER J M, BAXTER-STOLTZFUS A, et al. Targeting potential drivers of COVID-19:neutrophil extracellular traps[J]. J Exp Med, 2020, 217(6):e20200652.
|
[21] |
PASCOLINI S, VANNINI A, DELEONARDI G, et al. COVID-19 and immunological dysregulation:can autoantibodies be useful?[J]. ClinTransl Sci, 2021, 14(2):502-508.
|
[22] |
GAZZARUSO C, CARLO STELLA N, MARIANI G, et al. High prevalence of antinuclear antibodies and lupus anticoagulant in patients hospitalized for SARS-CoV2 pneumonia[J]. Clin Rheumatol, 2020, 39(7):2095-2097.
DOI
PMID
|
[23] |
LERMA L A, CHAUDHARY A, BRYAN A, et al. Prevalence of autoantibody responses in acute coronavirus disease 2019(COVID-19)[J]. J Transl Autoimmun, 2020, 3:100073.
DOI
URL
|
[24] |
SACCHI M C, TAMIAZZO S, STOBBIONE P, et al. SARS-CoV-2 infection as a trigger of autoimmune response[J]. ClinTransl Sci, 2021, 14(3):898-907.
|
[25] |
CHANG S E, FENG A, MENG W, et al. New-onset IgG autoantibodies in hospitalized patients with COVID-19[J]. Nat Commun, 2021, 12(1):5417.
DOI
PMID
|
[26] |
TRAHTEMBERG U, FRITZLER M J. On behalf of the COVID-19 chapter of the “Longitudinal Biomarkers in Lung Injury” study group. COVID-19-associated autoimmunity as a feature of acute respiratory failure[J]. Intensive Care Med, 2021, 47(7):801-804.
DOI
|
[27] |
CHANG S H, MINN D, KIM Y K. Autoantibodies in moderate and critical cases of COVID-19[J]. Clin Transl Sci, 2021, 14(5):1625-1626.
DOI
PMID
|
[28] |
KAMPF G, VOSS A, SCHEITHAUER S. Inactivation of coronaviruses by heat[J]. J Hosp Infect, 2020, 105(2):348-349.
DOI
PMID
|